6-K 1 zk1821797.htm 6-K

UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of June 2018
 
Commission File Number: 001-36187

EVOGENE LTD.
  (Translation of Registrant’s Name into English)
 
13 Gad Feinstein Street
Park Rehovot P.O.B 2100
Rehovot 7612002 Israel
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F x Form 40-F ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 

CONTENTS
 
The annual general meeting of shareholders (the “Meeting”) of Evogene Ltd. (“Evogene”) will be held at Evogene’s offices, located at 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel, on Tuesday, July 24, 2018 at 3:00 p.m., Israel time.  In connection with the Meeting, Evogene hereby furnishes the following documents:
 
Exhibit 99.1
Notice of the Meeting.
 
Exhibit 99.2
 
Exhibit 99.3
Proxy Statement for the Meeting.
           
Form of Proxy Card for the Meeting.
 
The foregoing exhibits are available on the Company’s website at http://www.evogene.com/investor-relations/.
 
This Form 6-K is incorporated by reference into the Company’s registration statements on Form S-8 (File Nos. 333-193788, 333-201443 and 333-203856).
 
2
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 



 Date: June 14, 2018
  
EVOGENE  LTD.
(Registrant)

By: /s/ Alex Taskar
Name: Alex Taskar
 Title: Chief Financial Officer
 
3
EXHIBIT INDEX
 
EXHIBIT NO.
DESCRIPTION
 
 

 
4